Neomorph, Inc., a San Diego, CA-based biotechnology company, raised $109m in Series A financing.
The company intends to use the funds to further develop its platform, advance lead programs, and expand the research team.
Deerfield Management Company established Neomorph earlier this year with scientific founders Phil Chamberlain, DPhil; Eric Fischer, PhD; Benjamin Ebert, MD, PhD; and Scott Armstrong, MD, PhD.
The company is building a protein degradation entity, focused on “molecular glue” degraders. Targeted protein degradation offers opportunities to develop novel therapeutics across a broad range of disease areas, including oncology.
Led by Dr. Chamberlain as President and Chief Scientific Officer, the company has recruited:
- Rohan Beckwith, PhD;
- Gang Lu, PhD;
- Mary Matyskiela, PhD;
- Ben Wen, PhD; and
- Samer Chmait.